Smith Giri1, Vijaya Raj Bhatt2, Vivek Verma3, Ranjan Pathak4, R Gregory Bociek2, Julie M Vose2, James O Armitage2. 1. Division of Hematology/Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT. Electronic address: smith.giri@yale.edu. 2. Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE. 3. Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE. 4. Department of Medicine, Reading Health System, Reading, PA.
Abstract
BACKGROUND: With the improving outcomes of patients with follicular lymphoma (FL), it is imperative to focus on survivorship issues, including the development of second primary malignancies (SPMs). We used a large US database to measure the risk of SPMs among FL survivors. MATERIALS AND METHODS: We used the Surveillance, Epidemiology, and End Results-13 registry to identify FL patients from 1992 to 2011. We calculated the risk of SPMs, developing ≥ 6 months after diagnosis, using the standardized incidence ratio (SIR) and absolute excess risk. We calculated the cumulative incidence of SPMs using the competing risk method and risk factors for SPMs using univariate and multivariate methods. RESULTS: Of a total of 15,517 patients with FL followed up for a median of 71 months, 1540 (9.9%) developed SPMs, with a SIR of 1.08 and absolute excess risk of 11.3 per 10,000 person-years. A significantly increased risk was noted for Hodgkin lymphoma (SIR, 5.85), acute myeloid leukemia (SIR, 4.88), and the following sites: oral cavity and pharynx (SIR, 1.43), stomach (SIR, 1.43), lung and bronchus (SIR, 1.35), melanoma of skin (SIR, 1.38), other nonepithelial cancers of the skin (SIR, 2.88), urinary bladder (SIR, 1.24), and kidney/renal pelvis (SIR, 1.43). The cumulative incidence of SPMs was 11.06% at 10 years. Multivariate regression showed that age > 65 years (SIR, 1.57; P < .001), male gender (SIR, 1.43; P < .001), and receipt of radiation (SIR, 1.24; P = .001) predicted a higher rate of SPMs. CONCLUSION: Patients with FL have increased risk of both hematologic and solid malignancies. Risk factors for SPMs include advanced age, male gender, and receipt of radiation therapy.
BACKGROUND: With the improving outcomes of patients with follicular lymphoma (FL), it is imperative to focus on survivorship issues, including the development of second primary malignancies (SPMs). We used a large US database to measure the risk of SPMs among FL survivors. MATERIALS AND METHODS: We used the Surveillance, Epidemiology, and End Results-13 registry to identify FL patients from 1992 to 2011. We calculated the risk of SPMs, developing ≥ 6 months after diagnosis, using the standardized incidence ratio (SIR) and absolute excess risk. We calculated the cumulative incidence of SPMs using the competing risk method and risk factors for SPMs using univariate and multivariate methods. RESULTS: Of a total of 15,517 patients with FL followed up for a median of 71 months, 1540 (9.9%) developed SPMs, with a SIR of 1.08 and absolute excess risk of 11.3 per 10,000 person-years. A significantly increased risk was noted for Hodgkin lymphoma (SIR, 5.85), acute myeloid leukemia (SIR, 4.88), and the following sites: oral cavity and pharynx (SIR, 1.43), stomach (SIR, 1.43), lung and bronchus (SIR, 1.35), melanoma of skin (SIR, 1.38), other nonepithelial cancers of the skin (SIR, 2.88), urinary bladder (SIR, 1.24), and kidney/renal pelvis (SIR, 1.43). The cumulative incidence of SPMs was 11.06% at 10 years. Multivariate regression showed that age > 65 years (SIR, 1.57; P < .001), male gender (SIR, 1.43; P < .001), and receipt of radiation (SIR, 1.24; P = .001) predicted a higher rate of SPMs. CONCLUSION:Patients with FL have increased risk of both hematologic and solid malignancies. Risk factors for SPMs include advanced age, male gender, and receipt of radiation therapy.
Authors: Ana Cordeiro; Evandro D Bezerra; Alexandre V Hirayama; Joshua A Hill; Qian V Wu; Jenna Voutsinas; Mohamed L Sorror; Cameron J Turtle; David G Maloney; Merav Bar Journal: Biol Blood Marrow Transplant Date: 2019-08-13 Impact factor: 5.742
Authors: Manette A W Dinnessen; Otto Visser; Sanne H Tonino; Marjolein W M van der Poel; Nicole M A Blijlevens; Marie José Kersten; Pieternella J Lugtenburg; Avinash G Dinmohamed Journal: EJHaem Date: 2020-10-08
Authors: Sara J Schonfeld; Lindsay M Morton; Amy Berrington de González; Rochelle E Curtis; Cari M Kitahara Journal: Cancer Epidemiol Date: 2019-12-26 Impact factor: 2.984
Authors: Jin Seok Kim; Yanfang Liu; Kyoung Hwa Ha; Hong Qiu; Lee Anne Rothwell; Hyeon Chang Kim Journal: Cancer Res Treat Date: 2020-05-04 Impact factor: 4.679
Authors: Manette A W Dinnessen; Otto Visser; Sanne H Tonino; Eduardus F M Posthuma; Nicole M A Blijlevens; Marie José Kersten; Pieternella J Lugtenburg; Avinash G Dinmohamed Journal: Blood Cancer J Date: 2021-11-13 Impact factor: 11.037
Authors: Caitlin Eichten; Qiufei Ma; Thomas E Delea; May Hagiwara; Roberto Ramos; Şerban R Iorga; Jie Zhang; Richard T Maziarz Journal: Pharmacoeconomics Date: 2021-07-17 Impact factor: 4.981